Compromising Patient Access Is Not a Path Forward for Alzheimer's Disease | Business

Retrieved on: 2022-04-08 17:44:21

Tags for this article:

Click the tags to see associated articles and topics

Compromising Patient Access Is Not a Path Forward for Alzheimer's Disease | Business. View article details on hiswai:

Excerpt

... Coverage with Evidence Development (NCD) for monoclonal antibodies (mABs) targeting amyloid for the treatment of Alzheimer's disease.

Article found on: www.valdostadailytimes.com